Download Curriculum Vitae Hardik Chandarana

CURRICULUM VITAE
HARDIK CHANDARANA
PERSONAL PARTICULARS:
NAME:
REG. NO.:
DOB:
NATIONALITY :
PASSPORT NO.:
RESIDENCE :
HARDIK CHANDARANA
GB I-17396
2ND DECEMBER , 1985
INDIAN
H8191162
I/401, GANESH HOMES,
B/H. SAHAJANAND RESIDENCY ,
CHENPUR ROAD, NEW RANIP, AHMEDABAD – 382480
CONTACT DETAILS :
CELL:
EMAIL:
BBM PIN:
SKYPE ID:
+91-9724501553
[email protected], [email protected]
2B3DBAB7
hardik212
]
ACADEMIC QUALIFICATION :
QUALIFICATION
BAMS
H.S.C.
S.S.C.
YEAR
2008
2003
2001
PERCENTAGE
56%
81%
84%
UNIVERSITY / BOARD
AKHANDANAND AYURVED COLLEGE , AHMEDABAD
GUJARAT HIGHER SECONDARY EDUCATION BOARD
GUJARAT SECONDARY EDUCATION BOARD
CLINICAL RESEARCH EXPERIENCES:
 STARTED RESEARCH SET UP AT DIA CARE NAMED “DIA CARE RESEARCH” IN AUGUST , 2008.
 EXPERIENCED WITH ICH-GCP GUIDELINES SINCE LAST 5 YEARS
 CURRENTLY WORKING WITH DIFFERENT CLINICAL TRIALS FOR TYPE 1 & TYPE 2 DIABETIC PATIENTS AND
OTHER M ETABOLIC D ISORDERS AS A
o HOD: CLINICAL RESEARCH DEPARTMENT
 JOB PROFILE :
 HANDLING CLINICAL RESEARCH DEPARTMENT ALONG WITH 6 CLINICAL
RESEARCH COORDINATOR
 RECRUITMENT AND TRAINING OF CLINICAL RESEARCH COORDINATOR
 COMMUNICATION WITH CROS & SMOS FOR CONDUCTING CLINICAL TRIALS AT
SITE

WEEKLY IN HOUSE MONITORING OF ONGOING CLINICAL TRIALS AT SITE
Page 1 of 7


ADMINISTRATION OF SITE
ADVERSE EVENT EVALUATION AND FOLLOW UP
o
SUB INVESTIGATOR :
 JOB PROFILE :
 INFORMED CONSENT PROCESS
 HISTORY TAKING AND PHYSICAL EXAMINATION
 VITAL SIGNS
 EVALUATION OF LAB REPORTS
 ADVERSE EVENT EVALUATION AND FOLLOW UP
o
CLINICAL RESEARCH COORDINATOR:
 JOB PROFILE:
 PARTICIPATION IN “STARTUP INVESTIGATOR MEET” AND ACTIVE FEEDBACK ON
PROTOCOL
 COMMUNICATION WITH ETHICS COMMITTEE AND SPONSOR
 SELECTION OF ELIGIBLE PATIENTS
 EVALUATION OF INCLUSION/EXCLUSION CRITERIA
 INFORMED CONSENT PROCESS
 PATIENTS RANDOMIZATION THROUGH IVRS AS WELL AS IWRS
 PRACTICAL TRIAL COORDINATION
 CRF COMPLETION – PAPER AS WELL AS E CRF
 SUBJECT FOLLOW UP AND RETENTION
 DEVICE TRAINING TO THE SUBJECTS I.E. GLUCOMETER , INJECTING DEVICE
 DRUG ACCOUNTABILITY
 MAINTENANCE OF INVESTIGATOR TRIAL FILE
 ADVERSE EVENT EVALUATION AND REPORTING OF SAE S
 FACING INTERIM MONITORING VISITS
 DATA PRESENTATION AT INTERIM EVALUATION AND CLOSEOUT MEETING
CLINICAL EXPERIENCES:
 WORKING AS A COORDINATOR FOR CHANGING DIABETES IN CHILDREN (CDIC) PROJECT SUPPORTED BY
ISPAD AT DIA CARE CENTRE , AHMEDABAD (I NDIA).
 WORKING AS A COORDINATOR FOR LIFE FOR A CHILD (LFAC) PROJECT SUPPORTED BY IDF AT DIA CARE
CENTRE , AHMEDABAD (INDIA).
 TRAINING ON DIABETIC FOOT IN FEBRUARY 2009 AT RAJKOT.
 WORKING AS A PODIATRIST AT DIA CARE, AHMEDABAD.
o PODIATRIST:
Page 2 of 7

JOB PROFILE :
 MINOR DRESSING AND OPERATIVE FOR DIABETIC FOOT PATIENTS
 EDUCATIONAL LECTURES FOR PATIENTS FOR PREVENTION OF DIABETIC FOOT BY
AUDIO-VISUAL PRESENTATION
 PERFORM DIAGNOSTIC TESTS FOR FOOT EXAMINATION I.E. VPT, ABI, FOOT
SCAN
 ADVISE PROPER CUSTOMIZED FOOTWEAR FOR HIGH RISK PATIENTS
CLINICAL TRIALS:




DIABETES NEPHROPATHY IN TYPE II DIABETIC PATIENTS (PHASE III/3 YEARS), IN 2008.
12 MONTHS STUDY OF NEW ONSET OF TYPE II DIABETES FOR OAD (PHASE III), IN 2008.
12 MONTHS STUDY OF DIABETES AND COPD, INHALE INSULIN IN TYPE II DM (PHASE III), IN 2009.
EFFICACY AND SAFETY OF TZD GROUP OF DRUG AS MONOTHERAPY TREATMENT OF TYPE II DM
(PHASE III), IN 2009.
 DIABETES NEPHROPATHY IN TYPE I & TYPE II DM (12 WEEKS / PHASE III), IN 2010.
 COMPARISON BETWEEN A NEWER OAD DRUG WITH SULFONYLUREA AS ADD ON THERAPY IN PATIENTS
WITH TYPE II DM, INADEQUATELY CONTROLLED ON OAD M ONOTHERAPY (PHASE III / 52 WEEKS),
IN 2010.
 COMPARATIVE EFFICACY OF TWO DIFFERENT OAD COMBINATION IN TYPE II DM (P HASE IIIA / 16
WEEKS), IN 2010.
 16 WEEKS POST MARKETING OBSERVATION STUDY FOR EMERGENT ADVERSE EVENT WITH TYPE II
DM, IN 2010.
 A NEWLY ORAL DPP-IV INHIBITOR IN PATIENTS WITH TYPE II DM (PHASE II), IN 2010.
 POST MARKETING SURVEILLANCE STUDY OF GLP – 1 ANALOGUE, IN 2010.
 COMPARISON OF EFFICACY & SAFETY BETWEEN MITIGLINIDE & NATEGLINIDE (PHASE IV), IN 2010.
 OBSTACLE HYPOGLYCEMIA STUDY IN PATIENTS WITH TYPE II DIABETES, IN 2010.
 COMPARISON OF EFFICACY & SAFETY BETWEEN SOLUBLE INSULIN A NALOGUE COMBINATION WITH
INSULIN GLARGINE, BOTH IN COMBINATION WITH OAD IN PATIENTS WITH TYPE II D IABETES (PHASE
IIIA), IN 2011.
 COMPARISON OF NEWER MOLECULE WITH PIOGLITAZONE IN DYSLIPIDEMIA WITH TYPE II DIABETES
PATIENTS (PHASE III), IN 2011.
 COMPARISON OF NEWER MOLECULE WITH PLACEBO IN HYPERTRIGLYSERIDEMIA WITH TYPE II DM NOT
CONTROLLED WITH ATORVASTATIN THERAPY (PHASE III), IN 2011.
 STUDY OF CANAGLIFLOZIN ON CARDIOVASCULAR OUTCOME IN ADULT SUBJECTS WITH TYPE II DM.
(CANVAS TRIAL), IN 2010.
 PHASE III COMPARATIVE STUDY OF RHGH WITH EUTROPIN IN TH TREATMENT OF PRE PUBERTAL CHILDREN
WITH GROWTH HORMONE DEFICIENCY , IN 2011.
 PHASE II STUDY ON GLYCEMIC CONTROL OF NEW MOLECULE (P1736-05) IN TYPE II DM SUBJECTS, IN
2011.
Page 3 of 7
 COMPARATIVE STUDY FOR THE IMMUNOGENICITY AND SAFETY OF WOCKHARDT ’S HUMAN INSULIN WITH
NOVO NORDISK’S YEAST BASED HUMAN INSULIN FOR TYPE I PATIENTS, IN 2011.
 PHASE III COMPARATIVE STUDY TO CHECK THE SAFETY OF INTAS PRODUCT AGAINST FORTEO OF ELI-LILLY IN
POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS , IN 2011.
 COMPARISON OF HYDROXYCHLOROQUINE WITH PIOGLITAZONE IN THE TREATMENT OF TYPE II DM
PATIENTS, IN 2012.
 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NEW MOLECULE COMPARED TO FENOFIBRATE IN
PATIENTS WITH DYSLIPIDEMIA, IN 2012
 A PHASE 3, RANDOMIZED , DOUBLE-BLIND, PLACEBO -CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE
THE EFFICACY AND S AFETY OF RANOLAZINE WHEN ADDED TO M ETFORMIN IN SUBJECTS WITH TYPE 2
DIABETES MELLITUS, ONGOING
 SAFETY AND EFFICACY OF TRC150094 IN TREATMENT OF CARDIO-METABOLIC RISK IN OVERWEIGHT/OBESE
PRE -DIABETIC SUBJECTS WITH D YSLIPIDEMIA , ONGOING
 USE OF IPROTM2 IN REAL LIFE DIABETES MANAGEMENT OF TYPE 2 PATIENTS IN INDIA, O NGOING
 COMPARATIVE EVALUATION OF EFFICACY AND S AFETY OF L OSARTAN - METOPROLOL XL COMBINATION VS.
LOSARTAN – RAMIPRIL COMBINATION IN PATIENTS WITH ESSENTIAL HYPERTENSION ALONG WITH TYPE II
DIABETES, ONGOING
 AN OPEN LABEL , RANDOMIZED COMPARISON OF THE SAFETY AND EFFICACY OF WOCKHARDT ’S INSULIN
ANALOGUE GLARGINE (GLARITUS) WITH SANOFI AVENTIS I NSULIN ANALOGUE GLARGINE (L ANTUS) GIVEN
ALONG WITH MEAL TIME BOLUS OF RAPID ACTING INSULIN (LISPRO ) IN TYPE 1 DIABETES PATIENTS ,
ONGOING
PRESENTATION OF SCIENTIFIC PAPER:
 KADAM – THERAPEUTIC INTERVENTIONS AND PREVENTIVE STRATEGIES FOR TYPE 2 DIABETES AT IDF 2011,
DUBAI (UAE)
 COMPARISON OF OUTCOME IN PREGNANCY IN TYPE 1 DIABETIC WOMAN ON CONTINUOUS
SUBCUTANEOUS INSULIN INFUSION V/S MULTIPLE DOSE INJECTION AT IDF 2011, DUBAI (UAE)
 COMPARISON OF OUTCOME IN PREGNANCY IN TYPE 1 DIABETIC WOMAN ON CONTINUOUS SUBCUTANEOUS
INSULIN INFUSION V / S MULTIPLE DOSE INJECTION AT ISPAD 2011, M IAMI (US)
 CHANGE IN QUALITY OF LIFE BY MULTIPLE EDUCATION PROGRAM IN TYPE 1 DIABETIC PATIENTS AT ISPAD
2011, MIAMI (US)
 PREVENTION OF DIABETIC FOOT ULCER IN HIGH RISK PATIENTS AT DFSICON 2011, AHMEDABAD
PUBLICATION:
 PREGNANCY OUTCOME AND GLYCEMIC CONTROL IN WOMEN WITH TYPE 1 DIABETES: A RETROSPECTIVE
COMPARISON BETWEEN CSII AND MDI TREATMENT
 A PROSPECTIVE STUDY : AN IMPROVEMENT OF QUALITY OF LIFE AND METABOLIC STATUS (HBA1C) WITH
MULTIPLE EDUCATIONAL PROGRAMS IN TYPE 1 DIABETIC (COMMUNICATED)
CHAPTER IN BOOK
Page 4 of 7
 WRITTEN A CHAPTER ON “ROLE OF PRIMARY CARE PHYSICIAN & MEDIA IN MANAGEMENT OF DIABETES” IN
ICP MONOGRAM, 2013
TEACHING EXPERIENCES:
 ORGANIZED DIABETES EDUCATORS WORKSHOP DURING 3RD WORLD CONFERENCE OF “DIABETES IN ASIA
STUDY GROUP” AT MUMBAI (INDIA) AND GIVEN LECTURE ON “DIABETIC FOOT” DURING THE WORKSHOP .
 INVITED AS A F ACULTY FOR DELIVERING A LECTURE ON DIABETES FOOT FOR 3RD WORLD CONFERENCE OF
DIABETES IN ASIA STUDY GROUP – DASG 2012 AT MUMBAI ON 14TH APRIL, 2012.
 INVITED AS A FACULTY FOR GIVING A VIDEO DEMONSTRATION ON “BASIC DIAGNOSTIC PROCEDURE FOR
SCREENING DIABETIC NEUROPATHY” AT 10TH ANNUAL CONFERENCE OF DIABETIC FOOT SOCIETY OF INDIA –
DFSICON 2012 AT HOTEL THE PARK, HYDERABAD ON 8TH SEPTEMBER , 2013. ALSO CONDUCTED HANDS
ON WORKSHOP DURING THE CONFERENCE .
 FACULTY FOR ROUTINE EDUCATION PROGRAM FOR HEALTH EDUCATORS AT AHMEDABAD
CONFERENCE ORGANIZED :
 ORGANIZED A NATIONAL CONFERENCE “AYU EXPO” IN 2004 AT TAGORE HALL, AHMEDABAD ATTENDED BY
500 DELEGATES.
 MEMBER OF LOCAL ORGANIZING COMMITTEE FOR THE NATIONAL CONFERENCE OF RESEARCH SOCIETY FOR
THE STUDY OF D IABETES IN INDIA – RSSDI2009 AT AHMEDABAD ATTENDED BY 25 INTERNATIONAL AND
200 NATIONAL FACULTIES AND 3000 DELEGATES
 ORGANIZED MANY TRAINING PROGRAMS FOR HEALTH EDUCATORS ALONG WITH WORLD DIABETES
FOUNDATION AND INDIAN DIABETES RESEARCH FOUNDATION AT AHMEDABAD.
COMMUNITY ACTIVITIES:
 TAKEN PART IN NSS CAMP IN RURAL AREA IN 2004 & 2006.
 ALSO ACTIVELY INVOLVED IN HEALTH CAMPAIGN AND HEALTH AWARENESS PROGRAM IN RURAL AREA .
 ACTIVELY INVOLVED IN ORGANIZING TRAINING PROGRAM FOR FAMILY PHYSICIANS AS WELL AS
PARAMEDICAL .
 PROJECT DIRECTOR FOR PROJECT “KADAM” – A DIABETES AWARENESS PROGRAM
 CURRENTLY PARTICIPATING AS A VOLUNTEER IN “DOSTI UNSTOPPABLE ” PROGRAM, RUN BY YUVA
UNSTOPPABLE – NGO AND TIMES FOUNDATION (MARCH 2010 - ONGOING)
 AN ACTIVE MEMBER OF NATION FIRST FOUNDATION TO SPREAD THE MESSAGE OF HINDUISM
ACCOMPLISHMENT:
 FIRST PRIZE WINNER OF “SCIENCE QUIZ” AT STATE LEVEL IN 2000 AT JAMNAGAR.
Page 5 of 7
 SECOND PRIZE WINNER OF ORAL PRESENTATION ON “PREVENTION OF DIABETIC FOOT ULCER IN HIGH RISK
PATIENTS” AT DFSICON 2011 AT AHMEDABAD.
TEHCNICAL PROFICIENCY:





OPERATING SYSTEM: WINDOWS XP, VISTA, WINDOWS 7, WINDOWS 8, IOS,
MS OFFICE: WORD, EXCEL, POWERPOINT, OUTLOOK
IP HONE , ANDROID P HONES, BLACKBERRY
INTERNET BROWSING
EXCELLENT TYPING SPEED: 71 WPM
DECLARATION:
I HEREBY DECLARE THAT THE INFORMATION FURNISHED ABOVE IS TRUE TO THE BEST OF MY KNOWLEDGE
DATE: ______________
SIGNATURE : _____________________
(HARDIK CHANDARANA)
Page 6 of 7
Page 7 of 7